Phase 2
Completed N=210
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
Methamphetamine Dependence
Source: ClinicalTrials.gov NCT00520286 ↗
Enrolled (actual)
210
Serious AEs
2.4%
Results posted
Apr 2017
Primary outcomePrimary: Abstinence (Week 1 - 12) — 27; 14; 38; 13 Participants
Summary
The purpose of this study will be to examine the safety and efficacy of modafinil in increasing number of methamphetamine non-use weeks in subjects with methamphetamine dependence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Abstinence (Week 1 - 12) |
27; 14; 38; 13; 39; 13 | — |
| SECONDARY Reduction of Craving |
32; 10 | — |
Eligibility Criteria
Inclusion Criteria
- Must be between the ages of 18 and 65
- Methamphetamine dependent as defined by DSM-IV criteria
- Must be in good general heath with a history of methamphetamine use at screening
- Must be able to provide written informed consent
- If female and of child bearing potential, must agree to use birth control.
Exclusion Criteria
- Please contact site for more information
Data sourced from ClinicalTrials.gov (NCT00520286). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.